Company profile: Petra Pharma
1.1 - Company Overview
Company description
- Provider of clinical-stage pharmaceutical development of novel therapies for serious medical conditions such as cancer and metabolic diseases, with a focus on novel enzyme targets that play a central role in cellular processes including cell division, growth, and trafficking.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Petra Pharma
Advanced Accelerator Applications
HQ: France
Website
- Description: Provider of targeted radioligand therapies and precision imaging radioligands, offering LUTATHERA: a radioligand therapy using lutetium Lu 177 dotatate for treating tumors; PLUVICTO: a therapeutic radioligand containing lutetium Lu 177 vipivotide tetraxetan; diagnostic PET imaging kits NETSPOT, LOCAMETZ, and SOMAKIT TOC; and LysaKare to reduce renal radiation exposure during peptide-receptor radionuclide therapy with LUTATHERA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Advanced Accelerator Applications company profile →
Phanes Therapeutics
HQ: United States
Website
- Description: Provider of therapeutics for solid tumors and eye diseases, offering PACbody, ATACCbody, and SPECpair platforms for native IgG-like and conjugated bispecific antibodies compatible with conventional monoclonal manufacturing, and a Phase 1 pipeline including PT199 (NSCLC, PDAC), PT886 (metastatic/advanced gastric, gastroesophageal junction, pancreatic adenocarcinoma), and PT217 (advanced refractory DLL3-expressing cancers).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Phanes Therapeutics company profile →
Tilt Biotherapeutics
HQ: Finland
Website
- Description: Provider of oncolytic viral cancer immunotherapies that enable tumor T-cell therapy by modifying the tumor microenvironment. Pipeline includes TILT-123 (cytokine-armed oncolytic adenovirus, in Phase 1), TILT-234 (Ad3 armed with human CD40L, ready for CMC/regulatory), TILT-321/322 (bispecific antibody-coding adenoviruses, discovery), and TILT-452 (preclinical), with clinical trial collaborations on TILT-123 with Merck KGaA and MSD.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tilt Biotherapeutics company profile →
Inovio
HQ: United States
Website
- Description: Provider of DNA medicines and delivery technologies for HPV-associated diseases, cancer and infectious diseases. Offerings include VGX-3100, a DNA plasmid therapeutic vaccine designed to treat HPV-related high-grade anal lesions; CELLECTRA electroporation devices delivering DNA medicines without chemical adjuvants, lipid nanoparticles or viral vectors; DMAb DNA-encoded monoclonal antibodies (including dMAb-1/2); and INO-5401, an experimental vaccine aimed at preventing cancer in BRCA1/2 carriers (Phase 1).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inovio company profile →
IOmet Pharma
HQ: United Kingdom
Website
- Description: Provider of novel small-molecule medicines for the treatment of cancer, discovered and developed in the UK with particular emphasis on cancer immunotherapy and cancer metabolism.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IOmet Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Petra Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Petra Pharma
2.2 - Growth funds investing in similar companies to Petra Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Petra Pharma
4.2 - Public trading comparable groups for Petra Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →